Objective: To study changes in myocardial wall texture in autosomal dominant polycystic kidney disease (ADPKD) patients by ultrasonic integrated backscatter (IBS) analysis. Methods: Hypertensive and normotensive ADPKD patients, essential hypertension (EHP) patients and healthy volunteers were included in the study. All the subjects underwent conventional echocardiography and ultrasonic IBS of the myocardial wall. Both the calibrated IBS (C-IBS) and the systolic-diastolic cyclical variations in IBS (CV-IBS) were evaluated. Results: Mean C-IBS in hypertensive ADPKD patients was significantly higher than that in EHP patients and normotensive ADPKD patients. Mean C-IBS in normotensive ADPKD patients was significantly higher than that in healthy subjects. Mean CV-IBS in hypertensive ADPKD patients was significantly lower than that in EHP patients and normotensive ADPKD patients. Mean CV-IBS in normotensive ADPKD patients was significantly lower than that in healthy subjects. Multivariate analysis showed that the mean C-IBS was positively related to the systolic and diastolic blood pressure (SBP, DBP) and left ventricular mass index (LVMI); mean CV-IBS was positively correlated with contractile performance and transmitral E/A ratio and inversely correlated with SBP, DBP and LVMI. Conclusions: ADPKD patients experienced myocardial interstitial collagen deposition and impairment to myocardial contractile performance, which were both aggravated by hypertension. IBS seems to be a useful tool for the assessment of myocardial changes in ADPKD patients.

1.
Fick-Brosnahan GM, Ecder T, Schrier R: Polycystic kidney disease; in Schrier RW (ed): Diseases of the Kidney and Urinary Tract, ed 7. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 547–588.
2.
Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048–2056.
3.
Harrap SB, Davies DL, Macnicol AM, et al: Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501–508.
4.
Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P: Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:118–123.
5.
Brunner HR: Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001;87:3C–9C.
6.
Hirsch AT, Pinto YM, Schunkert H, Dzau VJ: Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D–30D.
7.
Vakili BA, Okin PM, Devereux RB: Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334–341.
8.
Verdecchia P, Angeli F, Borgioni C, et al: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003;16:895–899.
9.
Devereux RB, Dahlof B, Gerdts E, et al: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456–1462.
10.
Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292–1297.
11.
Valero FA, Martinez-Vea A, Bardají A, et al: Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020–1026.
12.
Nozaki S, DeMaria AN, Helmer GA, Hammond HK: Detection of regional left ventricular dysfunction in early pacing-induced heart failure using ultrasonic integrated- backscatter. Circulation 1995;92:2676–2682.
13.
Masuyama T, St Goar FG, Tye TL, et al: Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle-dependent variation in integrated backscatter. Circulation 1989;80:925–934.
14.
Fujimoto S, Mizuno R, Nakagawa Y, Kimura A, Yamaji K, Yutani C, Dohi K, Nakano H: Ultrasonic tissue characterization in patients with dilated cardiomyopathy: comparison with findings from right ventricular endomyocardial biopsy. Int J Card Imaging 1999;15:391–396.
15.
Di Bello V, Giorgi D, Viacava P, et al: Severe aortic stenosis and myocardial function: diagnostic and prognostic usefulness of ultrasonic integrated backscatter analysis. Circulation 2004;110:849–855.
16.
Naito J, Masuyama T, Mano T, Kondo H, Yamamoto K, Nagano R, Doi Y, Hori M, Kamada T: Ultrasonic myocardial tissue characterization in patients with dilated cardiomyopathy: value in noninvasive assessment of myocardial fibrosis. Am Heart J 1996;131:115–121.
17.
Di Bello V, Giorgi D, Talini E, Dell’Omo G, Palagi C, Romano MF, Pedrinelli R, Mariani M: Incremental value of ultrasonic tissue characterization (backscatter) in the evaluation of left ventricular myocardial structure and mechanics in essential arterial hypertension. Circulation 2003;107:74–80.
18.
Salvetti M, Muiesan ML, Paini A, Monteduro C, Bonzi B, Galbassini G, Belotti E, Movilli E, Cancarini G, Agabiti-Rosei E: Myocardial ultrasound tissue characterization in patients with chronic renal failure. J Am Soc Nephrol 2007;18:1953–1958. Epub 2007.
19.
Galetta F, Bernini G, Franzoni F, et al: Preclinical cardiac involvement in phaeochromocytoma: a study with integrated backscatter. Clin Endocrinol (Oxf) 2008;68:756–761.
20.
Ma YC, Zuo L, Chen JH, et al: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937–2944.
21.
Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072–1083.
22.
Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613–618.
23.
Giovanni de Simone, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH: Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994;23:1444–1451.
24.
Mimbs JW, O’Donnell M, Bauwens D, Miller JW, Sobel BE: The dependence of ultrasonic attenuation and backscatter on collagen content in dog and rabbit hearts. Circ Res 1980;47:49–58.
25.
Rong S, Jin X, Ye C, Chen J, Mei C: Carotid vascular remodelling in patients with autosomal dominant polycystic kidney disease. Nephrology (Carlton) 2009;14:113–117.
26.
Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091–1096.
27.
Brilla CG, Reams GP, Maisch B, Weber KT: Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 1993;14(suppl J):57–61.
28.
Wickline SA, Thomas LJ 3rd, Miller JG, Sobel BE, Perez JE: A relationship between ultrasonic integrated backscatter and myocardial contractile function. J Clin Invest 1985;76:2151–2160.
29.
Fujimoto S, Mizuno R, Nakagawa Y, Kimura A, Yamaji K, Yutani C, Dohi K, Nakano H: Ultrasonic tissue characterization in patients with dilated cardiomyopathy: comparison with findings from right ventricular endomyocardial biopsy. Int J Card Imaging 1999;15:391–396.
30.
Maceira AM, Barba J, Varo N, Beloqui O, Díez J: Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002;39:923–928.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.